November 2025
1. JIAO B, Sato R, Mak J, Patenaude B, et al
   Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
   PLoS Med. 2025;22:e1004764.
   

   >> Share

   
   October 2025
2. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
   Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
   PLoS Med. 2025;22:e1004499.
   

   >> Share

   
   
3. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
   Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
   PLoS Med. 2025;22:e1004789.
   

   >> Share

   
   September 2025
4. MANDOLO J, Mulira L, Moyo M, Mvula M, et al
   Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.
   PLoS Med. 2025;22:e1004734.
   

   >> Share

   
   
5. JIN S, Asakura TR, Murayama H, Niyukuri D, et al
   Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study.
   PLoS Med. 2025;22:e1004726.
   

   >> Share

   
   July 2025
6. LI J, Li Y, Qin C, He Y, et al
   Effect of a pay-it-forward strategy on reducing HPV vaccine delay and increasing uptake among 15- to 18-year-old girls in China: A randomized controlled trial.
   PLoS Med. 2025;22:e1004535.
   

   >> Share

   
   June 2025
7. GOODFELLOW L, Procter SR, Koltai M, Waterlow NR, et al
   The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis.
   PLoS Med. 2025;22:e1004655.
   

   >> Share

   
   
8. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
   Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
   PLoS Med. 2025;22:e1004631.
   

   >> Share

   
   April 2025
9. 
   Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
   PLoS Med. 2025;22:e1004605.
   

   >> Share

   
   February 2025
10. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004521.
    

    >> Share

    
    
11. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
    Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004508.
    

    >> Share

    
    
12. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
    Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
    PLoS Med. 2025;22:e1004530.
    

    >> Share

    
    
13. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
    Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
    PLoS Med. 2025;22:e1004543.
    

    >> Share

    
    January 2025
14. SEIDLEIN LV
    Roll out and prospects of the malaria vaccine R21/Matrix-M.
    PLoS Med. 2025;22:e1004515.
    

    >> Share

    
    
15. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004573.
    

    >> Share

    
    October 2024
16. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
    Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
    PLoS Med. 2024;21:e1004466.
    

    >> Share

    
    September 2024
17. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    

    >> Share

    
    June 2024
18. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    

    >> Share

    
    
19. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    

    >> Share

    
    April 2024
20. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    

    >> Share

    
    March 2024
21. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share